Get the Stockscreener App
0.2762
1.56%
0.00425
Virpax Pharmaceuticals Inc stock is traded at $0.2762, with a volume of 248.29K.
It is up +1.56% in the last 24 hours and down -30.44% over the past month.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
See More
Previous Close:
$0.2719
Open:
$0.27
24h Volume:
248.29K
Relative Volume:
0.07
Market Cap:
$4.99M
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.0313
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
-11.52%
1M Performance:
-30.44%
6M Performance:
-72.66%
1Y Performance:
-92.75%
1-Day Range:
$0.265
$0.297
1-Week Range:
$0.265
$0.299
52-Week Range:
$0.23
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
610-727-4597
Address
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2777 | 4.99M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.04 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.12 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.27 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.78 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals Inc (VRPX) Stock: What the Analysts are Saying - The News Heater
Virpax Pharmaceuticals Appoints Charn Deol as Independent DirectorVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced on February 5, 2025, the appointment of Mr. Charn Deol as an independent director of the Company, effective immediately. Mr. D - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals appoints new independent director By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director - TipRanks
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals Board Member Jay Panis Resigns - TipRanks
Virpax Pharmaceuticals director resigns due to compliance - Investing.com
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Nanotechnology Stocks To Keep An Eye OnFebruary 03rd - MarketBeat
Promising Nanotechnology Stocks To Follow TodayFebruary 02nd - MarketBeat
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
VRPXVirpax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Clinical Trials Innovation: Virpax Leadership Takes Center Stage at Elite OCT Conference - StockTitan
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com India
Virpax Secures Critical $6M Funding: Game-Changing Move for Probudur Development - StockTitan
What's Going With Penny Stock Virpax Pharmaceuticals On Monday? - MSN
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Amendments to Independent Contractor Agreements at Virpax Pharmaceuticals Clarify Roles and Responsibilities - Defense World
Virpax Updates Executive Agreements for Legal Compliance - TipRanks
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals, Inc. Appoints Jaydriane Panis to the Board - Marketscreener.com
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals names new board director By Investing.com - Investing.com UK
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals announces board member resignation By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals Announces Board Member Resignation - TipRanks
Virpax Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com Canada
Virpax Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MSN
VRPX (Virpax Pharmaceuticals) Enterprise Value : $3.71 Mil (As of Dec. 01, 2024) - GuruFocus.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals lowers quorum requirement - Investing.com India
Virpax Pharmaceuticals : Amendments to Bylaws Form 8 K - Marketscreener.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):